Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
CHL is strengthening its play in the fast-growing beauty and personal care sector
The demand in Africa for COVID-19 vaccines has declined
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
A significant proportion of healthcare professionals still tend to favor branded drugs
Subscribe To Our Newsletter & Stay Updated
